#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Anal cancer recurrent Allogenic stem cell transplantation Porphyria non-acute Metastatic gastric cancer Synovial sarcoma recurrent Neuroendocrine carcinoma of the skin Epilepsy Neonatal asphyxia Thalassaemia beta Ductal adenocarcinoma of pancreas Alternating hemiplegia of childhood Squamous cell carcinoma of head and neck Ichthyosis Immunoglobulin G4 related disease Hodgkin's disease refractory More trials…

    Learn about Rare Diseases

    Medulloblastoma recurrent Hepatic angiosarcoma Toxic epidermal necrolysis – Life with Disease Ocular melanoma – Basic Information Urea cycle disorder Phenylketonuria – Treatment Basal cell naevus syndrome – Treatment Rosai-Dorfman syndrome – Treatment X-linked lymphoproliferative syndrome Osteosarcoma metastatic – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Atogepant Lanreotide Immunoglobulins, Normal Human JX10 Rifaximin Mps-112 Azd9550 Islatravir Sulfonamides, Urea Derivatives AP31969 SULFATE Amisulpride Insulin Icodec F510/08 IHMA-2121908-1 Xanthum Gum Sebetralstat Gd2Il18Cart Glucose Glatiramer Acetate Cft1946 More therapies…

    Learn about Your Condition

    Retinopathy of prematurity White matter lesion Polyneuropathy Glaucoma MELAS syndrome Alagille syndrome Hypercholesterolaemia Back pain Generalised anxiety disorder Laryngeal cancer stage I Monkeypox Testicular germ cell tumour Hyperkalaemia Delayed graft function Foetal growth restriction More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Noe LGA Gesundheit Region Mitte GmbH

Noe LGA Gesundheit Region Mitte GmbH

Alter Ziegelweg 10, St. Poelten, 3430, Austria

Want to learn more about this study or check if you can participate? Contact us.

  • Study of Pivekimab Sunirine Combined with Venetoclax and Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

    Recruiting

    4 1 1 1
    Investigated Drugs:
    • Azacitidine
    • Pivekimab Sunirine
    • Venetoclax
    Austria France Spain

  • Study of JNJ-78934804 (guselkumab and golimumab) versus guselkumab in adults with moderately to severely active Crohn’s disease

    Recruiting

    3 1 1
    Investigated Drugs:
    • Golimumab
    • Guselkumab
    Austria Belgium Czechia France Germany Greece +9

  • Efficacy and Safety of JNJ-78934804 (guselkumab and golimumab) in Adults with Moderately to Severely Active Ulcerative Colitis

    Recruiting

    3 1 1
    Investigated Drugs:
    • Golimumab
    • Guselkumab
    Austria Belgium Bulgaria Czechia Denmark France +11

  • Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

    Recruiting

    3 1 1
    Investigated Diseases:
    • Primary myelofibrosis
    • Myelofibrosis
    Investigated Drugs:
    • 2-((4S)-6-(4-Chlorophenyl)-1-Methyl-4H-Benzo[C]Isoxazolo[4,5-E]Azepin-4-Yl)Acetamide Monohydrate
    • Ruxolitinib
    Austria Belgium Czechia France Germany Italy +3

  • Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Pembrolizumab
    Austria Belgium Bulgaria Czechia Finland France +10

  • A study to evaluate the effectiveness of levosimendan in patients with pulmonary hypertension and heart failure with preserved ejection fraction.

    Recruiting

    3 1
    Investigated Diseases:
    • Pulmonary hypertension
    Investigated Drugs:
    • Levosimendan
    Austria Bulgaria Czechia France Germany Hungary +3

  • A study comparing odronextamab combined with chemotherapy versus rituximab combined with chemotherapy in adults with previously untreated follicular lymphoma

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Odronextamab
    • Cyclophosphamide
    • Doxorubicin Hydrochloride
    Austria Belgium Czechia France Germany Italy +2

  • Study of Revumenib and Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia with NPM1 Gene Mutation

    Recruiting

    3 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • Revumenib
    • Idarubicin Hydrochloride
    • Daunorubicin Hydrochloride
    Austria Belgium Czechia France Germany Greece +7

  • Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

    Recruiting

    3 1
    Investigated Drugs:
    • ZILEBESIRAN
    Austria Belgium Bulgaria Czechia Denmark France +11

  • A Study of Amivantamab With Carboplatin and Pembrolizumab for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Amivantamab
    • Carboplatin
    • Cisplatin
    Austria Belgium Czechia France Germany Hungary +6
1 2 3 … 9
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!